AbCellera Biologics Inc.

AbCellera Biologics (ABCL) filed an 8-K on August 13, 2026 (event date August 12) under Items 1.01 and 8.01, announcing a material definitive agreement alongside other events. The excerpt is the cover page; the specific agreement details are in the body. This 8-K was filed concurrently with AbCellera's prospectus supplement (424B5) for a share offering, suggesting the agreement may be related to the capital raise — potentially a licensing deal, collaboration, or stock purchase agreement with a counterparty. AbCellera is a clinical-stage antibody discovery company.

AbCellera Biologics (ABCL) filed a 424B5 prospectus supplement on August 13, 2026, pricing an equity offering of 17,435,897 shares of common stock plus 3,076,926 pre-funded warrants, with the last reported sale price cited as $10.36 per share. The total gross proceeds would be approximately $211M at that price, representing meaningful dilution for existing shareholders. The offering was filed the same day as AbCellera's 8-K announcing a material agreement, suggesting proceeds may be tied to a strategic transaction or clinical program funding. AbCellera is a clinical-stage antibody discovery and development company.

AbCellera Biologics (ABCL) is conducting a preliminary $200 million equity offering consisting of common shares and, for investors preferring not to hold shares immediately, pre-funded warrants exercisable at $0.00001 per share. This is a preliminary (subject to completion) prospectus supplement filed August 11, 2026; pricing has not yet been set. The last reported sale price on Nasdaq on August 10, 2026 was $9.32 per share. AbCellera is a Canadian company listed on Nasdaq, and investors are purchasing interests in a Canadian entity.

AbCellera Biologics Inc. (ABCL) filed a Reg FD disclosure (Item 7.01) on 2026-08-10, furnishing conference call and webcast at 4:30 a. Reg FD filings ensure simultaneous public disclosure of material information shared with select investors. This is generally an informational filing; no new deal terms or financial results were announced unless noted. Investors should review the attached exhibit for updated guidance or strategic commentary.

ABCL reported financial results for quarter. Full results are disclosed in a press release filed as Exhibit 99.1. Item 2.02 mandates simultaneous disclosure of material earnings data, ensuring all investors receive results at the same time. Investors should review the attached exhibit for complete financial figures and any forward guidance from ABCL management.

Lynn Seely filed an initial Form 3 as a newly appointed director of AbCellera Biologics Inc. (ABCL), effective June 30, 2026, disclosing no securities beneficially owned. This is a mandatory administrative filing upon becoming a Section 16 reporting person — no ownership stake or economic exposure to report.

AbCellera Biologics Inc. appointed Lynn Seely, M.D. as a new Class III director effective June 30, 2026, to serve until the 2029 annual meeting of shareholders or until her earlier resignation or removal. The Board determined Dr. Seely is independent under Nasdaq rules and she will participate in the company's standard Non-Employee Director Compensation Policy on the same terms as other non-employee directors. No committee assignments were made at this time, and she has no material related-party transactions with the company. This is a routine governance appointment — adding an independent director to the ABCL board with no significant strategic or financial implications beyond normal board compensation.

AbCellera Biologics Inc. held its 2026 Annual Meeting of Shareholders on June 11, 2026, with 305,264,947 shares eligible to vote. Shareholders elected Class III directors John S. Montalbano and Stephen R. Quake to three-year terms; ratified Ernst & Young LLP as auditor; and approved Say-on-Pay on a non-binding advisory basis — all three proposals passed. Routine annual governance vote with no contested proposals or material changes to compensation structure.